Skip to content

Research on AI-Based Facial Activity-Related Patterns and Digital Biomarkers in Progressive Supranuclear Palsy

Research on AI-Based Facial Activity-Related Patterns and Digital Biomarkers in Progressive Supranuclear Palsy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110752
Enrollment
Unknown
Registered
2025-10-20
Start date
2025-10-31
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Gold Standard:The 2017 Movement Disorder Society Progressive Supranuclear Palsy (PSP) Study Group Diagnostic Criteria?The 2015 Movement Disorder Society (MDS) Diagnostic Criteria for Parkinson's Disea
Index test:MDS UPDRS I-IV scales

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1Progressive Supranuclear Palsy (PSP) Group: (1) Patients diagnosed with definite or probable PSP according to the 2017 Movement Disorder Society PSP Study Group diagnostic criteria; (2) Participants aged 18 to 80 years (inclusive of boundary values), without limitation of sex; (3) Consent to undergo research-related evaluations and tests, and sign the informed consent form. 2Parkinson's Disease (PD) Group: (1) Patients diagnosed with definite Parkinson's disease according to the 2015 Movement Disorder Society (MDS) diagnostic criteria for Parkinson's disease; (2) Early-stage PD patients with a Hoehn-Yahr staging score of <= 2.5, and mid-to-late-stage PD patients with a Hoehn-Yahr staging score of 3-5; (3) Participants aged 18 to 80 years (inclusive of boundary values), without limitation of sex; (4) Consent to undergo research-related evaluations and tests, and sign the informed consent form. 3Healthy Control Group: (1) Participants aged 18 to 80 years (inclusive of boundary values), without limitation of sex; (2) Consent to undergo research-related evaluations and tests, and sign the informed consent form; (3) Denial of any other neurological diseases.

Exclusion criteria

Exclusion criteria: 1?Severe cognitive dysfunction, precluding the ability to complete the assessment paradigm. 2?Patients with significant organ failure (e.g., cardiac, pulmonary, hepatic, renal), malignancies, unstable medical conditions, or other severe internal medical diseases. 3?Individuals with severe behavioral issues or psychiatric disorders. 4?Inability to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Diagnostic Odds Ratio;Positive Predictive Value;Specificity;Accuracy;Negative Predictive Value;Sensitivity;

Countries

China

Contacts

Public ContactJennifer

Beijing Tiantan Hospital, Capital Medical University

Jennifer_MLY@163.com+86 10 5997 6611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026